Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study

Jeeyun Lee, Se Hoon Park, Heung Moon Chang, Jun Suk Kim, Hye Jin Choi, Myung Ah Lee, Joung Soon Chang, Hei Cheul Jeung, Jung Hun Kang, Hyun Woo Lee, Dong Bok Shin, Hye Jin Kang, Jong Mu Sun, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim

Research output: Contribution to journalArticle

244 Citations (Scopus)

Abstract

Background: Combination chemotherapy with gemcitabine and a platinum-based agent is regarded as a standard treatment for patients with advanced biliary-tract cancer. Results of phase 2 trials of single-agent erlotinib in biliary-tract cancer and of gemcitabine plus erlotinib in pancreatic cancer have shown modest benefits. Therefore, we aimed to investigate the efficacy of gemcitabine and oxaliplatin plus erlotinib versus chemotherapy alone for advanced biliary-tract cancer. Methods: In this open label, randomised, phase 3 trial, we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer) to receive either first-line treatment with chemotherapy alone (gemcitabine 1000 mg/m 2 on day 1 and oxaliplatin 100 mg/m 2 on day 2) or chemotherapy plus erlotinib (100 mg daily). Treatment was repeated every 2 weeks until disease progression or unacceptable toxic effects. Randomisation was done centrally (stratified by participating centre and presence of measurable lesion). The primary endpoint was progression-free survival. Analyses were by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT01149122. Findings: 133 patients were randomly assigned to the chemotherapy alone group and 135 to the chemotherapy plus erlotinib group. The groups were balanced except for a higher proportion of patients with cholangiocarcinoma in the group given erlotinib than in the chemotherapy alone group (96 [71%] patients vs 84 [63%]). Median progression-free survival was 4·2 months (95% CI 2·7-5·7) in the chemotherapy alone group and 5·8 months (95% CI 4·6-7·0) in the chemotherapy plus erlotinib group (hazard ratio [HR] 0·80, 95% CI 0·61-1·03; p=0·087). Significantly more patients had an objective response in the chemotherapy plus erlotinib group than in the chemotherapy alone group (40 patients vs 21 patients; p=0·005), but median overall survival was the same in both groups (9·5 months [95% CI 7·5-11·5] in the chemotherapy alone group and 9·5 months [7·6-11·4] in the chemotherapy plus erlotinib group; HR 0·93, 0·69-1·25; p=0·611). All-cause deaths within 30 days of random assignment occurred in one (1%) of the patients in the chemotherapy alone group and in four (3%) of those in the chemotherapy plus erlotinib group. The most common grade 3-4 adverse event was febrile neutropenia (eight [6%] patients in the chemotherapy alone group and six [4%] in the chemotherapy plus erlotinib group). No patient died of treatment-related causes during the study. Subgroup analyses by primary site of disease showed that for patients with cholangiocarcinoma, the addition of erlotinib to chemotherapy significantly prolonged median progression-free survival (5·9 months [95% CI 4·7-7·1] for chemotherapy plus erlotinib vs 3·0 months [1·1-4·9] for chemotherapy alone; HR 0·73, 95% CI 0·53-1·00; p=0·049). Interpretation: Although no significant difference in progression-free survival was noted between groups, the addition of erlotinib to gemcitabine and oxaliplatin showed antitumour activity and might be a treatment option for patients with cholangiocarcinoma. Funding: None.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalThe Lancet Oncology
Volume13
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

oxaliplatin
gemcitabine
Biliary Tract Neoplasms
Drug Therapy
Cholangiocarcinoma
Disease-Free Survival
Erlotinib Hydrochloride
Gallbladder Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer : A multicentre, open-label, randomised, phase 3 study. / Lee, Jeeyun; Park, Se Hoon; Chang, Heung Moon; Kim, Jun Suk; Choi, Hye Jin; Lee, Myung Ah; Chang, Joung Soon; Jeung, Hei Cheul; Kang, Jung Hun; Lee, Hyun Woo; Shin, Dong Bok; Kang, Hye Jin; Sun, Jong Mu; Park, Joon Oh; Park, Young Suk; Kang, Won Ki; Lim, Ho Yeong.

In: The Lancet Oncology, Vol. 13, No. 2, 01.02.2012, p. 181-188.

Research output: Contribution to journalArticle

Lee, J, Park, SH, Chang, HM, Kim, JS, Choi, HJ, Lee, MA, Chang, JS, Jeung, HC, Kang, JH, Lee, HW, Shin, DB, Kang, HJ, Sun, JM, Park, JO, Park, YS, Kang, WK & Lim, HY 2012, 'Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study', The Lancet Oncology, vol. 13, no. 2, pp. 181-188. https://doi.org/10.1016/S1470-2045(11)70301-1
Lee, Jeeyun ; Park, Se Hoon ; Chang, Heung Moon ; Kim, Jun Suk ; Choi, Hye Jin ; Lee, Myung Ah ; Chang, Joung Soon ; Jeung, Hei Cheul ; Kang, Jung Hun ; Lee, Hyun Woo ; Shin, Dong Bok ; Kang, Hye Jin ; Sun, Jong Mu ; Park, Joon Oh ; Park, Young Suk ; Kang, Won Ki ; Lim, Ho Yeong. / Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer : A multicentre, open-label, randomised, phase 3 study. In: The Lancet Oncology. 2012 ; Vol. 13, No. 2. pp. 181-188.
@article{f6ee7eab75da4956b208c47948cf83eb,
title = "Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study",
abstract = "Background: Combination chemotherapy with gemcitabine and a platinum-based agent is regarded as a standard treatment for patients with advanced biliary-tract cancer. Results of phase 2 trials of single-agent erlotinib in biliary-tract cancer and of gemcitabine plus erlotinib in pancreatic cancer have shown modest benefits. Therefore, we aimed to investigate the efficacy of gemcitabine and oxaliplatin plus erlotinib versus chemotherapy alone for advanced biliary-tract cancer. Methods: In this open label, randomised, phase 3 trial, we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer) to receive either first-line treatment with chemotherapy alone (gemcitabine 1000 mg/m 2 on day 1 and oxaliplatin 100 mg/m 2 on day 2) or chemotherapy plus erlotinib (100 mg daily). Treatment was repeated every 2 weeks until disease progression or unacceptable toxic effects. Randomisation was done centrally (stratified by participating centre and presence of measurable lesion). The primary endpoint was progression-free survival. Analyses were by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT01149122. Findings: 133 patients were randomly assigned to the chemotherapy alone group and 135 to the chemotherapy plus erlotinib group. The groups were balanced except for a higher proportion of patients with cholangiocarcinoma in the group given erlotinib than in the chemotherapy alone group (96 [71{\%}] patients vs 84 [63{\%}]). Median progression-free survival was 4·2 months (95{\%} CI 2·7-5·7) in the chemotherapy alone group and 5·8 months (95{\%} CI 4·6-7·0) in the chemotherapy plus erlotinib group (hazard ratio [HR] 0·80, 95{\%} CI 0·61-1·03; p=0·087). Significantly more patients had an objective response in the chemotherapy plus erlotinib group than in the chemotherapy alone group (40 patients vs 21 patients; p=0·005), but median overall survival was the same in both groups (9·5 months [95{\%} CI 7·5-11·5] in the chemotherapy alone group and 9·5 months [7·6-11·4] in the chemotherapy plus erlotinib group; HR 0·93, 0·69-1·25; p=0·611). All-cause deaths within 30 days of random assignment occurred in one (1{\%}) of the patients in the chemotherapy alone group and in four (3{\%}) of those in the chemotherapy plus erlotinib group. The most common grade 3-4 adverse event was febrile neutropenia (eight [6{\%}] patients in the chemotherapy alone group and six [4{\%}] in the chemotherapy plus erlotinib group). No patient died of treatment-related causes during the study. Subgroup analyses by primary site of disease showed that for patients with cholangiocarcinoma, the addition of erlotinib to chemotherapy significantly prolonged median progression-free survival (5·9 months [95{\%} CI 4·7-7·1] for chemotherapy plus erlotinib vs 3·0 months [1·1-4·9] for chemotherapy alone; HR 0·73, 95{\%} CI 0·53-1·00; p=0·049). Interpretation: Although no significant difference in progression-free survival was noted between groups, the addition of erlotinib to gemcitabine and oxaliplatin showed antitumour activity and might be a treatment option for patients with cholangiocarcinoma. Funding: None.",
author = "Jeeyun Lee and Park, {Se Hoon} and Chang, {Heung Moon} and Kim, {Jun Suk} and Choi, {Hye Jin} and Lee, {Myung Ah} and Chang, {Joung Soon} and Jeung, {Hei Cheul} and Kang, {Jung Hun} and Lee, {Hyun Woo} and Shin, {Dong Bok} and Kang, {Hye Jin} and Sun, {Jong Mu} and Park, {Joon Oh} and Park, {Young Suk} and Kang, {Won Ki} and Lim, {Ho Yeong}",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/S1470-2045(11)70301-1",
language = "English",
volume = "13",
pages = "181--188",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "2",

}

TY - JOUR

T1 - Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer

T2 - A multicentre, open-label, randomised, phase 3 study

AU - Lee, Jeeyun

AU - Park, Se Hoon

AU - Chang, Heung Moon

AU - Kim, Jun Suk

AU - Choi, Hye Jin

AU - Lee, Myung Ah

AU - Chang, Joung Soon

AU - Jeung, Hei Cheul

AU - Kang, Jung Hun

AU - Lee, Hyun Woo

AU - Shin, Dong Bok

AU - Kang, Hye Jin

AU - Sun, Jong Mu

AU - Park, Joon Oh

AU - Park, Young Suk

AU - Kang, Won Ki

AU - Lim, Ho Yeong

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background: Combination chemotherapy with gemcitabine and a platinum-based agent is regarded as a standard treatment for patients with advanced biliary-tract cancer. Results of phase 2 trials of single-agent erlotinib in biliary-tract cancer and of gemcitabine plus erlotinib in pancreatic cancer have shown modest benefits. Therefore, we aimed to investigate the efficacy of gemcitabine and oxaliplatin plus erlotinib versus chemotherapy alone for advanced biliary-tract cancer. Methods: In this open label, randomised, phase 3 trial, we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer) to receive either first-line treatment with chemotherapy alone (gemcitabine 1000 mg/m 2 on day 1 and oxaliplatin 100 mg/m 2 on day 2) or chemotherapy plus erlotinib (100 mg daily). Treatment was repeated every 2 weeks until disease progression or unacceptable toxic effects. Randomisation was done centrally (stratified by participating centre and presence of measurable lesion). The primary endpoint was progression-free survival. Analyses were by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT01149122. Findings: 133 patients were randomly assigned to the chemotherapy alone group and 135 to the chemotherapy plus erlotinib group. The groups were balanced except for a higher proportion of patients with cholangiocarcinoma in the group given erlotinib than in the chemotherapy alone group (96 [71%] patients vs 84 [63%]). Median progression-free survival was 4·2 months (95% CI 2·7-5·7) in the chemotherapy alone group and 5·8 months (95% CI 4·6-7·0) in the chemotherapy plus erlotinib group (hazard ratio [HR] 0·80, 95% CI 0·61-1·03; p=0·087). Significantly more patients had an objective response in the chemotherapy plus erlotinib group than in the chemotherapy alone group (40 patients vs 21 patients; p=0·005), but median overall survival was the same in both groups (9·5 months [95% CI 7·5-11·5] in the chemotherapy alone group and 9·5 months [7·6-11·4] in the chemotherapy plus erlotinib group; HR 0·93, 0·69-1·25; p=0·611). All-cause deaths within 30 days of random assignment occurred in one (1%) of the patients in the chemotherapy alone group and in four (3%) of those in the chemotherapy plus erlotinib group. The most common grade 3-4 adverse event was febrile neutropenia (eight [6%] patients in the chemotherapy alone group and six [4%] in the chemotherapy plus erlotinib group). No patient died of treatment-related causes during the study. Subgroup analyses by primary site of disease showed that for patients with cholangiocarcinoma, the addition of erlotinib to chemotherapy significantly prolonged median progression-free survival (5·9 months [95% CI 4·7-7·1] for chemotherapy plus erlotinib vs 3·0 months [1·1-4·9] for chemotherapy alone; HR 0·73, 95% CI 0·53-1·00; p=0·049). Interpretation: Although no significant difference in progression-free survival was noted between groups, the addition of erlotinib to gemcitabine and oxaliplatin showed antitumour activity and might be a treatment option for patients with cholangiocarcinoma. Funding: None.

AB - Background: Combination chemotherapy with gemcitabine and a platinum-based agent is regarded as a standard treatment for patients with advanced biliary-tract cancer. Results of phase 2 trials of single-agent erlotinib in biliary-tract cancer and of gemcitabine plus erlotinib in pancreatic cancer have shown modest benefits. Therefore, we aimed to investigate the efficacy of gemcitabine and oxaliplatin plus erlotinib versus chemotherapy alone for advanced biliary-tract cancer. Methods: In this open label, randomised, phase 3 trial, we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer) to receive either first-line treatment with chemotherapy alone (gemcitabine 1000 mg/m 2 on day 1 and oxaliplatin 100 mg/m 2 on day 2) or chemotherapy plus erlotinib (100 mg daily). Treatment was repeated every 2 weeks until disease progression or unacceptable toxic effects. Randomisation was done centrally (stratified by participating centre and presence of measurable lesion). The primary endpoint was progression-free survival. Analyses were by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT01149122. Findings: 133 patients were randomly assigned to the chemotherapy alone group and 135 to the chemotherapy plus erlotinib group. The groups were balanced except for a higher proportion of patients with cholangiocarcinoma in the group given erlotinib than in the chemotherapy alone group (96 [71%] patients vs 84 [63%]). Median progression-free survival was 4·2 months (95% CI 2·7-5·7) in the chemotherapy alone group and 5·8 months (95% CI 4·6-7·0) in the chemotherapy plus erlotinib group (hazard ratio [HR] 0·80, 95% CI 0·61-1·03; p=0·087). Significantly more patients had an objective response in the chemotherapy plus erlotinib group than in the chemotherapy alone group (40 patients vs 21 patients; p=0·005), but median overall survival was the same in both groups (9·5 months [95% CI 7·5-11·5] in the chemotherapy alone group and 9·5 months [7·6-11·4] in the chemotherapy plus erlotinib group; HR 0·93, 0·69-1·25; p=0·611). All-cause deaths within 30 days of random assignment occurred in one (1%) of the patients in the chemotherapy alone group and in four (3%) of those in the chemotherapy plus erlotinib group. The most common grade 3-4 adverse event was febrile neutropenia (eight [6%] patients in the chemotherapy alone group and six [4%] in the chemotherapy plus erlotinib group). No patient died of treatment-related causes during the study. Subgroup analyses by primary site of disease showed that for patients with cholangiocarcinoma, the addition of erlotinib to chemotherapy significantly prolonged median progression-free survival (5·9 months [95% CI 4·7-7·1] for chemotherapy plus erlotinib vs 3·0 months [1·1-4·9] for chemotherapy alone; HR 0·73, 95% CI 0·53-1·00; p=0·049). Interpretation: Although no significant difference in progression-free survival was noted between groups, the addition of erlotinib to gemcitabine and oxaliplatin showed antitumour activity and might be a treatment option for patients with cholangiocarcinoma. Funding: None.

UR - http://www.scopus.com/inward/record.url?scp=84856476387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856476387&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(11)70301-1

DO - 10.1016/S1470-2045(11)70301-1

M3 - Article

C2 - 22192731

AN - SCOPUS:84856476387

VL - 13

SP - 181

EP - 188

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 2

ER -